GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » PB Ratio

Oncopeptides AB (LTS:0RN4) PB Ratio : 2.40 (As of Dec. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Oncopeptides AB's share price is kr1.538. Oncopeptides AB's Book Value per Share for the quarter that ended in Sep. 2024 was kr0.64. Hence, Oncopeptides AB's PB Ratio of today is 2.40.

The historical rank and industry rank for Oncopeptides AB's PB Ratio or its related term are showing as below:

LTS:0RN4' s PB Ratio Range Over the Past 10 Years
Min: 0.48   Med: 3.73   Max: 59
Current: 2.4

During the past 10 years, Oncopeptides AB's highest PB Ratio was 59.00. The lowest was 0.48. And the median was 3.73.

LTS:0RN4's PB Ratio is ranked better than
50.98% of 1279 companies
in the Biotechnology industry
Industry Median: 2.52 vs LTS:0RN4: 2.40

During the past 12 months, Oncopeptides AB's average Book Value Per Share Growth Rate was -38.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -58.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -38.20% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncopeptides AB was 276.70% per year. The lowest was -58.00% per year. And the median was -14.65% per year.

Back to Basics: PB Ratio


Oncopeptides AB PB Ratio Historical Data

The historical data trend for Oncopeptides AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB PB Ratio Chart

Oncopeptides AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.00 20.33 3.01 3.82 12.44

Oncopeptides AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.91 12.44 - 3.09 3.36

Competitive Comparison of Oncopeptides AB's PB Ratio

For the Biotechnology subindustry, Oncopeptides AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's PB Ratio falls into.



Oncopeptides AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Oncopeptides AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.538/0.642
=2.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Oncopeptides AB  (LTS:0RN4) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Oncopeptides AB PB Ratio Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines